CD4 and myeloid sarcoma: We longitudinally followed 40 patients with MS before and after one-year natalizumab treatment, examining the numbers and proportions of circulating CD4+ and CD8+ T cells, Treg cells, B cells, NK cells, NKT cells as well as markers of activation and co-stimulation.